🔴 Connect Biopharma is trading 5% down today after mixed second-quarter results and a widening net loss

Connect Biopharma is trading 5% down now at $2.41 after mixed second-quarter results and a widened net loss.

• Collaboration revenue: $2.8 million, above estimates; net loss: $17.3 million, widened on higher research spending.
• The stock rose 9.01% to $2.54 August 13; Phase 2 asthma and COPD enrollment is complete, with topline results expected September 2026.
• Major indexes are near flat; earnings digestion/profit-taking appear likelier than broad weakness. No separate major August 14 company announcement or volume catalyst was identified.